Clinical TrialsThe first patient was dosed in the dose expansion part of the ongoing Phase 1 trial for CureVac’s multiepitope cancer vaccine candidate, CVGBM, in patients with resected glioblastoma.
Financial PerformanceCureVac reported 2Q24 results, ending the quarter with €202.5M and receiving the €400M upfront from GSK for COVID-19/flu in August, bringing estimated pro forma cash to €602.5M.
Strategic RestructuringCureVac announced modification of its GSK collaboration, internal restructuring to prioritize oncology and other selected diseases, and a 30% workforce reduction.